Turn Therapeutics (NASDAQ:TTRX) Trading 9.5% Higher – Still a Buy? - American Market News
Author: ABMN Staff
Description: Read Turn Therapeutics (NASDAQ:TTRX) Trading 9.5% Higher – Still a Buy? at American Market News
Keywords: Turn Therapeutics,NASDAQ:TTRX,TTRX,Manufacturing,Stocks,Technicals
Date: 2026-06-11T01:45:07+0000

Skip to main content

# Turn Therapeutics (NASDAQ:TTRX) Trading 9.5% Higher – Still a Buy?

Posted by ABMN Staff on Jun 11th, 2026

Share on Twitter
Share on Facebook
Share on LinkedIn
Share on Stocktwits

Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report)’s stock price traded up 9.5% on Wednesday . The stock traded as high as $5.97 and last traded at $5.53. 61,128 shares changed hands during mid-day trading, a decline of 6% from the average session volume of 64,995 shares. The stock had previously closed at $5.05.

Get Turn Therapeutics alerts:

## Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Turn Therapeutics has an average rating of “Hold” and a consensus target price of $8.00.

Read Our Latest Stock Analysis on Turn Therapeutics

## Turn Therapeutics Trading Up 9.5%

The company has a current ratio of 2.23, a quick ratio of 2.23 and a debt-to-equity ratio of 0.97. The firm has a market cap of $164.74 million and a price-to-earnings ratio of -29.11. The firm’s 50-day moving average is $4.20 and its 200-day moving average is $3.90.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

## Institutional Trading of Turn Therapeutics

Several institutional investors have recently made changes to their positions in TTRX. Millennium Management LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $377,000. Wellington Shields & Co. LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $259,000. XTX Topco Ltd bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $99,000. Brown Brothers Harriman & Co. bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $93,000. Finally, HighTower Advisors LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $78,000.

## Turn Therapeutics Company Profile

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

## Further Reading

- Five stocks we like better than Turn Therapeutics
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You

Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

## You might be interested in:

YD Bio Trading Up 3.1% – Still a Buy?
Artius II Acquisition Shares Down 5.8% – Here’s Why
Nomadar Trading 0.6% Higher – Still a Buy?
Off The Hook Ys Stock Price Down 5.2% – Here’s Why
Top Win International Trading 2.3% Higher – Should You Buy?
Turn Therapeutics Trading 9.5% Higher – Still a Buy?